-
サマリー
あらすじ・解説
Metastatic HER2-positive breast cancer continues to dominate headlines, and new therapeutic options continue to be found for those afflicted with the disease. Before trastuzumab (anti-HER2 therapy), the overall survival for this cohort of patients was less than two years. As technology and treatments changed, it can boast an extended survival well beyond five years in numerous studies, with many patients responding far more than that number.
This week, we will discuss two exciting and pioneering studies. The first looks at tucatinib, a tyrosine kinase inhibitor with known results in those with intracranial disease. The second is the use of abemaciclib in hormone receptor-positive, HER2-positive breast cancer in patients previously treated with trastuzumab.
Links to studies discussed in this episode (subscription may be required):
HER2CLIMB: Link
monarcHER: Link
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Please find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com
Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.
Art courtesy of Taryn Silver
Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.